Physician profile
Stuart I Levin
NPI 1053303446
$6,376.48
in general payments reported to CMS, 2019-2025
26 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,678 · 2020: $846 · 2021: $971 · 2022: $303 · 2023: $1,256 · 2024: $387 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,579.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,479.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,338.60 | 2020-2025 | Wegovy |
| Amgen INC. | $599.26 | 2019-2021 | |
| Abbvie INC. | $507.60 | 2019-2024 | |
| Glaxosmithkline, LLC. | $342.20 | 2021-2023 | Arexvy, Shingrix |
| Astellas Pharma US INC | $237.83 | 2019-2023 | Veozah |
| Coloplast Corp | $199.02 | 2023 | Titan, Altis |
| Lilly USA, LLC | $196.05 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $156.12 | 2019 | |
| Silk Road Medical, INC. | $134.31 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Merck Sharp & Dohme LLC | $123.18 | 2019-2024 | Verquvo, Gardasil, Capvaxive |
| Boston Scientific Corporation | $122.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $122.06 | 2019 | |
| Akcea Therapeutics, INC. | $121.02 | 2019 | |
| Tactile Systems Technology INC | $116.11 | 2025 | Nimbl, Flexitouch Plus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $113.07 | 2023 | Qelbree |
| Novartis Pharmaceuticals Corporation | $86.87 | 2019 | |
| Teleflex LLC | $86.59 | 2025 | Barrigel |
| Medtronic, INC. | $77.78 | 2025 | Venaseal |
| Pfizer INC. | $65.55 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $47.90 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $29.85 | 2023 | |
| Eisai INC. | $24.97 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $17.01 | 2021 | |
| Sanofi Pasteur INC. | $16.11 | 2019 | |
| Linus Health, INC. | $15.13 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.